The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.
You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.
We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.
We are interested in where in or outside the cell the gene product carries out its function.
We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.
Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.
The requested target is correctly identified as human S-phase kinase-associated protein 2 (SKP2; FBXL1; UniProt Q13309). The literature consistently describes an approximately 45-kDa F-box/leucine-rich-repeat protein matching the supplied names and domain annotation; no conflicting same-symbol protein was encountered. SKP2 is not a kinase despite its historical name, and it is not the catalytic ubiquitin-transfer subunit. Its primary function is to act as the substrate receptor of the SCF^SKP2 Cullin–RING E3 ubiquitin ligase. The F-box binds SKP1, whereas the C-terminal leucine-rich repeats and accessory factors recognize substrates. The remaining SCF core consists principally of CUL1 and RBX1, with RBX1 recruiting a ubiquitin-charged E2 enzyme. Thus, “SKP2 E3 ligase” is shorthand for the assembled complex rather than isolated SKP2 enzymatic activity. (nesson2024skpingcellcycle pages 2-3, nesson2024skpingcellcycle pages 14-15, frescas2008deregulatedproteolysisby pages 2-4)
The best-established physiological reaction is phosphorylation-dependent ubiquitination of p27^KIP1/CDKN1B. CDK2–cyclin A or E phosphorylates p27 at Thr187; CKS1 and SKP2 then form a composite phosphodegron receptor, leading to p27 polyubiquitination and 26S-proteasomal degradation. Loss of this CDK inhibitor releases cyclin–CDK activity and facilitates G1/S progression. Structural, biochemical, and genetic evidence makes this much firmer than many of the broader substrate assignments reported for SKP2. (nesson2024skpingcellcycle pages 14-15, frescas2008deregulatedproteolysisby pages 2-4, frescas2008deregulatedproteolysisby pages 13-14, skaar2014scfubiquitinligasetargeted pages 8-9)
Some secondary articles describe a “WD40 region” in SKP2. That terminology should not supersede the well-established FBXL classification: the defining C-terminal substrate-binding architecture of SKP2 is leucine-rich-repeat based. The supplied Q13309 identity is therefore internally consistent and sufficiently unambiguous for annotation.
SCF complexes are modular Cullin–RING ubiquitin ligases. In SCF^SKP2:
SKP2 has no independent reaction analogous to an enzyme with a freely diffusible small-molecule substrate. Its “substrate specificity” is protein- and state-specific: it preferentially recognizes particular proteins after phosphorylation or assembly into a suitable multiprotein complex. Ubiquitin transfer itself is executed by the E2–SCF machinery after SKP2 recruits the substrate. (nesson2024skpingcellcycle pages 14-15, frescas2008deregulatedproteolysisby pages 2-4)
The mechanistic sequence is:
SKP2 abundance is low in quiescence and early G1, rises around G1/S, and peaks during S phase, inversely tracking p27 stability. SKP2 disruption causes p27 accumulation and G1 restraint. In mouse genetics, Skp2 loss also produces polyploidy, centrosome overduplication, and cyclin-E accumulation; removal of p27 reverses many Skp2-null phenotypes. This epistasis is strong evidence that p27 is a major physiological effector rather than merely an in-vitro substrate. (nesson2024skpingcellcycle pages 2-3, nesson2024skpingcellcycle pages 14-15, frescas2008deregulatedproteolysisby pages 13-14)
Reported proteolytic substrates include p21^CIP1, p57^KIP2, p130, FOXO1, RASSF1A, TOB1, BRCA2, CDT1, ORC1, RAG2, E2F1, MYC and several cyclins or transcriptional regulators. These assignments are not equally secure: some have purified-system, abundance, and genetic evidence, whereas others rest primarily on co-immunoprecipitation, overexpression, or context-specific cellular experiments. p27 remains the reference mechanism against which other assignments should be judged. (nesson2024skpingcellcycle pages 2-3, nesson2024skpingcellcycle pages 1-2, frescas2008deregulatedproteolysisby pages 13-14, frescas2008deregulatedproteolysisby pages 21-23)
SKP2 can also support nonproteolytic K63-linked ubiquitination. Reported examples include AKT1 ubiquitination that promotes membrane recruitment and activation, and YAP ubiquitination that enhances TEAD interaction, nuclear localization, and transcriptional activity. These findings establish that the outcome is not invariably proteasomal destruction: linkage type, E2 enzyme, substrate, and cellular context determine whether ubiquitination changes stability, localization, or signaling. Nevertheless, these pathways are less universally established than p27 proteolysis. (gupta2026moleculardynamicssimulations pages 2-3, zheng2026skp2incancer pages 16-17)
Canonical Thr187-dependent p27 destruction is principally a nuclear event associated with active cell-cycle progression. SKP2 is not permanently restricted to the nucleus, however. Phosphorylation and acetylation can stabilize it and redistribute a fraction to the cytoplasm, where context-specific signaling substrates become accessible. Reported regulatory modifications include CDK-linked phosphorylation that protects SKP2 from APC/C^CDH1, AKT-associated Ser72 phosphorylation and 14-3-3-dependent cytoplasmic redistribution, and p300-mediated acetylation of Lys68/Lys71 that promotes stability and cytoplasmic retention. (frescas2008deregulatedproteolysisby pages 21-23, zheng2026skp2incancer pages 18-19, zheng2026skp2incancer pages 6-7)
During G1, APC/C^CDH1 ubiquitinates SKP2, helping maintain high p27 and low CDK activity. As APC/C^CDH1 activity declines near G1/S, SKP2 accumulates and SCF^SKP2 activity rises. This reciprocal use of two ubiquitin-ligase systems creates a switch-like transition into S phase. Nuclear and cytoplasmic SKP2 measurements must therefore be interpreted with cell-cycle state, growth-factor signaling, and post-translational modifications in mind. (frescas2008deregulatedproteolysisby pages 21-23)
The core functional axis is:
mitogenic signaling → cyclin E/A–CDK2 activation → p27 Thr187 phosphorylation → CKS1–SCF^SKP2 recognition → p27 ubiquitination/degradation → further CDK activation → DNA-replication commitment.
This creates positive feedback: initial CDK activity marks its inhibitor for destruction, reinforcing the G1/S transition. SCF^SKP2 also connects cell-cycle progression with DNA replication and repair through reported substrates such as CDT1 and BRCA2. (frescas2008deregulatedproteolysisby pages 2-4, nesson2024skpingcellcycle pages 1-2, frescas2008deregulatedproteolysisby pages 21-23)
Context-dependent links include PI3K–AKT signaling, Hippo/YAP signaling, autophagy, inflammatory signaling, DNA-damage responses, and transcriptional regulation. For example, K63-linked AKT or YAP ubiquitination can increase pathway output without degrading the substrate. Recent studies also implicate SKP2-mediated NLRP3 ubiquitination in restraining inflammasome activation and propose SKP2-dependent handling of ACSL4 in ferroptosis regulation. These newer assignments are biologically plausible but more model-dependent than the cell-cycle mechanism and require broader replication before being treated as universal SKP2 functions. (gupta2026moleculardynamicssimulations pages 2-3, zheng2026skp2incancer pages 19-20, zheng2026skp2incancer pages 16-17)
SKP2 is frequently described as a proto-oncogenic substrate receptor because its elevation lowers inhibitors such as p27 and can activate growth-promoting signaling. High SKP2 and low p27 have been associated with aggressive behavior or adverse prognosis in numerous cancers, including hematologic malignancies. Expert reviews nevertheless emphasize tumor and cellular context: expression can vary across cancer types, and an association does not by itself prove that a tumor is dependent on SKP2. (nesson2024skpingcellcycle pages 2-3, frescas2008deregulatedproteolysisby pages 2-4, skaar2014scfubiquitinligasetargeted pages 8-9)
Current applications are primarily research and preclinical:
The following evidence map summarizes the major findings and their limitations.
| Topic | Key finding | Evidence type/model | Date and source/DOI URL | Interpretation/limitation |
|---|---|---|---|---|
| Identity and architecture | The target is human SKP2 (UniProt Q13309; alias FBXL1), an approximately 45-kDa FBXL-family protein. Its F-box binds SKP1, while its C-terminal leucine-rich repeats form the principal substrate-binding surface. | Protein annotation, structural studies, and authoritative reviews | March 15, 2024, Nesson et al., Frontiers in Oncology, 10.3389/fonc.2024.1288501; November 2020, Mason and Laman, Open Biology, 10.1098/rsob.200319 (nesson2024skpingcellcycle pages 2-3, nesson2024skpingcellcycle pages 1-2) | Matches the supplied UniProt identity, organism, aliases, and F-box/LRR architecture; no conflicting same-symbol protein was identified. Some secondary sources describe a WD40 region, but SKP2 is classified by its LRRs as an FBXL protein. |
| Primary molecular function | SKP2 is the substrate-recognition receptor, not the catalytic ubiquitin-transfer subunit, of the SCF–SKP2 Cullin–RING E3 ligase containing SKP1, CUL1, and RBX1. It positions selected substrates near the RBX1-bound, ubiquitin-charged E2 enzyme. | SCF structural biology, biochemical reconstitution, and reviews | November 2000, Schulman et al., Nature, 10.1038/35042620; June 2008, Frescas and Pagano, Nature Reviews Cancer, 10.1038/nrc2396 (nesson2024skpingcellcycle pages 14-15, frescas2008deregulatedproteolysisby pages 2-4) | “E3 ubiquitin ligase SKP2” is common shorthand for the assembled SCF–SKP2 complex; isolated SKP2 is not an autonomous catalytic enzyme. |
| Canonical SCF–p27 mechanism | CDK2–cyclin A/E phosphorylates p27 at Thr187. CKS1 and the SKP2 LRR surface jointly recognize this phosphodegron, enabling p27 polyubiquitination and 26S-proteasomal degradation; removal of p27 inhibition activates CDK–cyclin complexes and promotes G1/S progression. | Human crystal structure, purified biochemical assays, and cell-cycle genetics | October 2005, Hao et al., Molecular Cell, 10.1016/j.molcel.2005.09.003; May 2007, Xu et al., JBC, 10.1074/jbc.M610758200 (nesson2024skpingcellcycle pages 14-15, frescas2008deregulatedproteolysisby pages 2-4, skaar2014scfubiquitinligasetargeted pages 8-9) | This is SKP2’s best-established substrate mechanism. CKS1 and prior substrate phosphorylation confer specificity; broader substrate lists vary considerably in evidential strength. |
| Genetic support for the p27 axis | Skp2 disruption causes p27 accumulation, cell-cycle restraint, polyploidy, and centrosome abnormalities; deletion of p27 rescues many Skp2-null phenotypes, indicating that p27 is a major physiological SKP2 effector. | Knockout and genetic-epistasis studies in mice and cells | June 2008 review of primary genetic evidence, Frescas and Pagano, 10.1038/nrc2396 (nesson2024skpingcellcycle pages 14-15, frescas2008deregulatedproteolysisby pages 13-14) | Genetic rescue provides strong causal evidence, although it does not imply that every SKP2 phenotype or disease association is mediated solely by p27. |
| Localization and regulation | Canonical p27 turnover occurs predominantly in the nucleus. SKP2 is low in G0/G1, rises at G1/S, and peaks in S phase; APC/C–CDH1 promotes its destruction in G1. Phosphorylation or acetylation can stabilize SKP2 and redistribute a pool to the cytoplasm. | Cell biology, post-translational-modification studies, and reviews | July 2012, Inuzuka et al., Cell, 10.1016/j.cell.2012.05.038; March 2024 review, 10.3389/fonc.2024.1288501 (nesson2024skpingcellcycle pages 2-3, frescas2008deregulatedproteolysisby pages 21-23, zheng2026skp2incancer pages 6-7) | Localization is dynamic rather than exclusively nuclear or cytoplasmic. Modification-dependent cytoplasmic functions are context specific, and some proposed regulatory effects remain debated across models. |
| Nonproteolytic K63 signaling | SCF–SKP2 can catalyze K63-linked ubiquitination with signaling rather than degradative outcomes. Reported examples include AKT activation and membrane recruitment, and YAP ubiquitination that promotes TEAD interaction, nuclear localization, and transcriptional activity. | Biochemical and cell-based pathway studies | June 2018, Yao et al., Nature Communications, 10.1038/s41467-018-04620-y (gupta2026moleculardynamicssimulations pages 2-3, zheng2026skp2incancer pages 16-17) | These findings broaden SKP2 beyond proteolysis, but they are less universally established than p27 degradation and may depend on cell type, E2 enzyme, substrate, and signaling state. |
| 2024 osteosarcoma findings | In Rb1/Trp53-deficient osteosarcoma models, additional Skp2 loss delayed tumorigenesis and improved survival. C1 and the broad neddylation inhibitor pevonedistat reduced xenograft growth, with reported growth-test values of P=0.009 and P=0.022, respectively; combinations with doxorubicin were also examined. | Genetically engineered mice, organoids, primary cultures, and NSG-mouse xenografts; at least five mice per treatment group in the reported experiment | February 2024, Wang et al., Oncogene, 10.1038/s41388-024-02942-4 (wang2024targetedinhibitionof pages 1-2, wang2024targetedinhibitionof pages 10-13, wang2024targetedinhibitionof pages 13-13) | Strong preclinical target validation, but small cohorts, subcutaneous tumors, immunodeficient hosts, and model-specific dosing limit clinical inference. Pevonedistat inhibits cullin neddylation broadly and is not SKP2-selective. |
| 2024 castration-resistant prostate cancer | Combined pharmacologic targeting of androgen-receptor and SKP2 pathways reduced proliferation in CRPC cell lines and xenografts and was more effective than either intervention alone in an invasive Pten/Trp53-deficient mouse model. SKP2 blockade was linked to autophagy-dependent apoptosis and renewed androgen-pathway responsiveness. | Human CRPC cell lines, humanized-mouse xenografts, and genetically engineered mouse tumors | December 2024, Celada et al., Science Signaling, 10.1126/scisignal.adk4122 (zheng2026skp2incancer pages 16-17) | Supports combination therapy conceptually, but remains preclinical; efficacy and safety in patients and the selectivity of the tool compound require clinical validation. |
| Translational status | Interaction disruptors such as SKPin C1 and SZL-P1-41, as well as indirect SCF inhibitors such as pevonedistat, show activity in cells or animal models. The reviewed registry search found no relevant clinical trial of a direct, selective SKP2 inhibitor. | Medicinal chemistry, preclinical cancer models, and clinical-trial registry search | 2023–2024 evidence synthesis; February 2024 osteosarcoma study, 10.1038/s41388-024-02942-4 (wang2024targetedinhibitionof pages 1-2, zheng2026skp2incancer pages 16-17) | Direct SKP2 inhibitors remain preclinical. Key barriers include protein–protein-interface druggability, selectivity within SCF biology, pharmacokinetics, toxicity, and the absence of validated predictive biomarkers. |
Table: Compact evidence map covering the verified identity, molecular mechanism, localization, signaling functions, and recent translational research on human SKP2. It distinguishes the established SCF–p27 mechanism from context-dependent signaling and preclinical therapeutic findings.
Wang et al. reported in February 2024 that additional Skp2 deletion in an Rb1/Trp53-deficient osteosarcoma model delayed tumorigenesis, improved overall survival, increased apoptosis, and reduced stemness-associated characteristics. In xenograft experiments with at least five mice per group, C1 and pevonedistat affected tumor growth with reported P=0.009 and P=0.022, respectively. Doses reported across experimental sections included C1 at 40–50 mg/kg/day and pevonedistat at 90 mg/kg/day; combinations with doxorubicin were evaluated in primary cultures. Body weights did not differ significantly at the reported time points. (wang2024targetedinhibitionof pages 1-2, wang2024targetedinhibitionof pages 10-13, wang2024targetedinhibitionof pages 13-13)
These results provide useful target validation but not clinical proof. The models included subcutaneous transplantation and immunodeficient NSG mice, cohorts were small, and pevonedistat broadly inhibits Cullin neddylation rather than selectively inhibiting SKP2. The clinical need is substantial—the paper notes five-year survival below 30% for overt metastatic or relapsed osteosarcoma—but whether selective SKP2 inhibition improves human outcomes remains unknown. The article is available at https://doi.org/10.1038/s41388-024-02942-4. (wang2024targetedinhibitionof pages 1-2, wang2024targetedinhibitionof pages 13-13)
A December 2024 Science Signaling study found that combined AR- and SKP2-pathway inhibition reduced proliferation in two CRPC cell lines, xenografts, and an invasive Pten/Trp53-deficient mouse model more effectively than either intervention alone. SKP2 blockade induced autophagy-dependent apoptosis and promoted a luminal-associated state that restored responsiveness to AR-directed therapy. This supports a combination-treatment hypothesis, but the evidence remains preclinical and depends partly on tool-compound selectivity. URL: https://doi.org/10.1126/scisignal.adk4122.
A March 15, 2024 review summarized SKP2 dysregulation across leukemias, lymphomas, and myeloma, emphasizing p27 destruction, treatment resistance, and generally adverse disease behavior. Its analysis also found that SKP2 expression is not uniformly increased in every cancer dataset, reinforcing the need for tumor-specific biomarkers rather than assuming universal dependency. URL: https://doi.org/10.3389/fonc.2024.1288501. (nesson2024skpingcellcycle pages 2-3, nesson2024skpingcellcycle pages 1-2)
A 2024 sepsis-associated lung-injury study proposed that HSPA8 loss promotes SKP2 degradation, reduces NLRP3 ubiquitination, and intensifies inflammasome-dependent alveolar epithelial pyroptosis; AAV9-mediated SKP2 expression reportedly increased NLRP3 ubiquitination and alleviated injury in mice. A separate 2024 prostate-cancer study linked an AKT–SKP2–ACSL4 axis to ferroptosis control. These findings expand SKP2 biology beyond proliferation but are currently disease-model-specific and should not displace p27 turnover as the primary functional annotation.
Several experimental compounds have been described, including SKPin C1, SZL-P1-41, and inhibitors aimed at the SKP2–CKS1 or SKP2–SKP1 interfaces. Earlier structure-guided inhibitors stabilized nuclear p27, induced G1 arrest, and reduced proliferation; in an endometrial model, reported results included a 14.3 μM cellular IC50, a 1.8-fold increase in nuclear p27, and a 42–62% reduction in epithelial proliferation in estrogen-primed mice. Those data established proof of mechanism but not clinical utility. (nesson2024skpingcellcycle pages 14-15, zheng2026skp2incancer pages 16-17)
The present evidence supports the following expert interpretation:
High confidence
Moderate confidence/context dependent
Emerging/preclinical
The most defensible primary annotation for human SKP2 is: a cell-cycle-regulated F-box/LRR substrate receptor that assembles into SCF^SKP2 and, together with CKS1, recognizes phosphorylated p27 for ubiquitination and proteasomal destruction, thereby activating cyclin–CDK signaling and facilitating S-phase entry. Its functional location is chiefly the nucleus for canonical p27 turnover, with regulated cytoplasmic pools mediating selected signaling functions. Recent 2024 work strengthens SKP2 as a therapeutic vulnerability in osteosarcoma and CRPC and extends its biology into inflammation and ferroptosis, but direct selective inhibitors have not yet achieved validated clinical implementation.
References
(nesson2024skpingcellcycle pages 2-3): Jonahunnatha Nesson, George William, Ruby Dhar, Rohit Gundamaraju, O. S. Sahoo, Karthikeyan Pethusamy, A. F. P. Allwin, Mabes Raj, Subbiah Ramasamy, M. Alqahtani, Mohamed Abbas, S. Karmakar, Michael Liew, Peter Wang, and Javier Leon. Skping cell cycle regulation: role of ubiquitin ligase skp2 in hematological malignancies. Frontiers in Oncology, Mar 2024. URL: https://doi.org/10.3389/fonc.2024.1288501, doi:10.3389/fonc.2024.1288501. This article has 27 citations.
(nesson2024skpingcellcycle pages 14-15): Jonahunnatha Nesson, George William, Ruby Dhar, Rohit Gundamaraju, O. S. Sahoo, Karthikeyan Pethusamy, A. F. P. Allwin, Mabes Raj, Subbiah Ramasamy, M. Alqahtani, Mohamed Abbas, S. Karmakar, Michael Liew, Peter Wang, and Javier Leon. Skping cell cycle regulation: role of ubiquitin ligase skp2 in hematological malignancies. Frontiers in Oncology, Mar 2024. URL: https://doi.org/10.3389/fonc.2024.1288501, doi:10.3389/fonc.2024.1288501. This article has 27 citations.
(frescas2008deregulatedproteolysisby pages 2-4): David Frescas and Michele Pagano. Deregulated proteolysis by the f-box proteins skp2 and β-trcp: tipping the scales of cancer. Nature Reviews Cancer, 8:438-449, Jun 2008. URL: https://doi.org/10.1038/nrc2396, doi:10.1038/nrc2396. This article has 1132 citations and is from a domain leading peer-reviewed journal.
(frescas2008deregulatedproteolysisby pages 13-14): David Frescas and Michele Pagano. Deregulated proteolysis by the f-box proteins skp2 and β-trcp: tipping the scales of cancer. Nature Reviews Cancer, 8:438-449, Jun 2008. URL: https://doi.org/10.1038/nrc2396, doi:10.1038/nrc2396. This article has 1132 citations and is from a domain leading peer-reviewed journal.
(skaar2014scfubiquitinligasetargeted pages 8-9): Jeffrey R. Skaar, Julia K. Pagan, and Michele Pagano. Scf ubiquitin ligase-targeted therapies. Nature Reviews Drug Discovery, 13:889-903, Nov 2014. URL: https://doi.org/10.1038/nrd4432, doi:10.1038/nrd4432. This article has 398 citations and is from a highest quality peer-reviewed journal.
(nesson2024skpingcellcycle pages 1-2): Jonahunnatha Nesson, George William, Ruby Dhar, Rohit Gundamaraju, O. S. Sahoo, Karthikeyan Pethusamy, A. F. P. Allwin, Mabes Raj, Subbiah Ramasamy, M. Alqahtani, Mohamed Abbas, S. Karmakar, Michael Liew, Peter Wang, and Javier Leon. Skping cell cycle regulation: role of ubiquitin ligase skp2 in hematological malignancies. Frontiers in Oncology, Mar 2024. URL: https://doi.org/10.3389/fonc.2024.1288501, doi:10.3389/fonc.2024.1288501. This article has 27 citations.
(frescas2008deregulatedproteolysisby pages 21-23): David Frescas and Michele Pagano. Deregulated proteolysis by the f-box proteins skp2 and β-trcp: tipping the scales of cancer. Nature Reviews Cancer, 8:438-449, Jun 2008. URL: https://doi.org/10.1038/nrc2396, doi:10.1038/nrc2396. This article has 1132 citations and is from a domain leading peer-reviewed journal.
(gupta2026moleculardynamicssimulations pages 2-3): Manshi Kumari Gupta and C. Sudandiradoss. Molecular dynamics simulations for understanding dual ubiquitination mechanisms to consider s-phase kinase-associated protein 2 (skp2) as a potential drug target in breast cancer. Frontiers in Chemistry, May 2026. URL: https://doi.org/10.3389/fchem.2026.1786015, doi:10.3389/fchem.2026.1786015. This article has 0 citations.
(zheng2026skp2incancer pages 16-17): Sheng-An Zheng, Cheng Wang, Xiao-Die Yao, Jia-Jia Sheng, Po-Wu Liu, Ying Wang, Shi-Jia Deng, and He Li. Skp2 in cancer: from molecular regulation to therapeutic vulnerabilities and translational perspectives. Drug Design, Development and Therapy, Volume 20:1-24, Aug 2026. URL: https://doi.org/10.2147/dddt.s619670, doi:10.2147/dddt.s619670. This article has 0 citations.
(zheng2026skp2incancer pages 18-19): Sheng-An Zheng, Cheng Wang, Xiao-Die Yao, Jia-Jia Sheng, Po-Wu Liu, Ying Wang, Shi-Jia Deng, and He Li. Skp2 in cancer: from molecular regulation to therapeutic vulnerabilities and translational perspectives. Drug Design, Development and Therapy, Volume 20:1-24, Aug 2026. URL: https://doi.org/10.2147/dddt.s619670, doi:10.2147/dddt.s619670. This article has 0 citations.
(zheng2026skp2incancer pages 6-7): Sheng-An Zheng, Cheng Wang, Xiao-Die Yao, Jia-Jia Sheng, Po-Wu Liu, Ying Wang, Shi-Jia Deng, and He Li. Skp2 in cancer: from molecular regulation to therapeutic vulnerabilities and translational perspectives. Drug Design, Development and Therapy, Volume 20:1-24, Aug 2026. URL: https://doi.org/10.2147/dddt.s619670, doi:10.2147/dddt.s619670. This article has 0 citations.
(zheng2026skp2incancer pages 19-20): Sheng-An Zheng, Cheng Wang, Xiao-Die Yao, Jia-Jia Sheng, Po-Wu Liu, Ying Wang, Shi-Jia Deng, and He Li. Skp2 in cancer: from molecular regulation to therapeutic vulnerabilities and translational perspectives. Drug Design, Development and Therapy, Volume 20:1-24, Aug 2026. URL: https://doi.org/10.2147/dddt.s619670, doi:10.2147/dddt.s619670. This article has 0 citations.
(wang2024targetedinhibitionof pages 1-2): Jichuan Wang, Alexander Ferrena, Ranxin Zhang, Swapnil Singh, Valentina Viscarret, Waleed Al-Harden, Osama Aldahamsheh, Hasibagan Borjihan, Amit Singla, Simon Yaguare, Janet Tingling, Xiaolin Zi, Yungtai Lo, Richard Gorlick, Edward L. Schwartz, Hongling Zhao, Rui Yang, David S. Geller, Deyou Zheng, and Bang H. Hoang. Targeted inhibition of scfskp2 confers anti-tumor activities resulting in a survival benefit in osteosarcoma. Oncogene, 43:962-975, Feb 2024. URL: https://doi.org/10.1038/s41388-024-02942-4, doi:10.1038/s41388-024-02942-4. This article has 26 citations and is from a domain leading peer-reviewed journal.
(wang2024targetedinhibitionof pages 10-13): Jichuan Wang, Alexander Ferrena, Ranxin Zhang, Swapnil Singh, Valentina Viscarret, Waleed Al-Harden, Osama Aldahamsheh, Hasibagan Borjihan, Amit Singla, Simon Yaguare, Janet Tingling, Xiaolin Zi, Yungtai Lo, Richard Gorlick, Edward L. Schwartz, Hongling Zhao, Rui Yang, David S. Geller, Deyou Zheng, and Bang H. Hoang. Targeted inhibition of scfskp2 confers anti-tumor activities resulting in a survival benefit in osteosarcoma. Oncogene, 43:962-975, Feb 2024. URL: https://doi.org/10.1038/s41388-024-02942-4, doi:10.1038/s41388-024-02942-4. This article has 26 citations and is from a domain leading peer-reviewed journal.
(wang2024targetedinhibitionof pages 13-13): Jichuan Wang, Alexander Ferrena, Ranxin Zhang, Swapnil Singh, Valentina Viscarret, Waleed Al-Harden, Osama Aldahamsheh, Hasibagan Borjihan, Amit Singla, Simon Yaguare, Janet Tingling, Xiaolin Zi, Yungtai Lo, Richard Gorlick, Edward L. Schwartz, Hongling Zhao, Rui Yang, David S. Geller, Deyou Zheng, and Bang H. Hoang. Targeted inhibition of scfskp2 confers anti-tumor activities resulting in a survival benefit in osteosarcoma. Oncogene, 43:962-975, Feb 2024. URL: https://doi.org/10.1038/s41388-024-02942-4, doi:10.1038/s41388-024-02942-4. This article has 26 citations and is from a domain leading peer-reviewed journal.